Singapore markets open in 3 hours 2 minutes

IGM Biosciences, Inc. (IGMS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
26.71+1.91 (+7.70%)
At close: 04:00PM EDT
26.00 -0.71 (-2.66%)
After hours: 05:25PM EDT

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
https://igmbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees217

Key executives

NameTitlePayExercisedYear born
Mr. Fred M. Schwarzer J.D.CEO, Pres & Director926.9kN/A1953
Dr. Lisa L. Decker Ph.D.Chief Bus. Officer528.18kN/A1969
Dr. Chris H. Takimoto FACP, M.D., Ph.D.Chief Medical Officer662.28kN/A1959
Mr. Misbah TahirChief Financial OfficerN/AN/A1975
Mr. Steven WeberSVP, Corp. Controller & Principal Accounting OfficerN/AN/A1976
Dr. Bruce A. KeytChief Scientific OfficerN/AN/A1953
Mr. Paul C. GraffagninoVP of Legal AffairsN/AN/AN/A
Ms. Suzette TauberChief HR OfficerN/AN/A1964
Dr. Shinyu Chen M.D., Ph.D.ConsultantN/AN/A1969
Dr. Angus M. Sinclair Ph.D.Sr. VP of Immuno-OncologyN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Corporate governance

IGM Biosciences, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.